Jeremy Clark

Jeremy Clark is a Research Fellow at the Norwich Medical School, University of East Anglia, and a member of the Metabolic Health research group. His work focuses on advancing non-invasive diagnostics for prostate cancer, particularly through urine-based biomarkers.

Research Interests: His research spans prostate cancer biology, urine-based diagnostics, molecular oncology, microbiome interactions, and clinical risk modeling. He aims to improve early detection, risk stratification, and treatment outcomes through translational research.

The most recent articles highlight a strong trend in integrating multimodal biomarkers—such as urinary peptides, cell-free RNA, extracellular vesicles, and microbiome data—into predictive models for prostate cancer detection and prognosis. His work emphasizes non-invasive, liquid biopsy approaches to reduce reliance on invasive biopsies and improve patient outcomes.

Scientific Recognition:

• Research widely covered in over 278 news outlets.
• Featured in press releases by UEA on breakthrough urine tests for prostate cancer.
• Work referenced in patents and Wikipedia, indicating high impact.
• Active media engagement as a medical expert in cancer diagnostics.

Grants and Projects: Clark is a co-investigator on multiple funded projects, including those from Prostate Cancer UK, the Hargrave Foundation, and the Royal Society. These projects focus on urine risk classifiers, bacterial infection roles in cancer, and parallel urine-biopsy analysis. While student advising is not explicitly mentioned, his collaborative projects suggest leadership in research teams.

Labs and Teams: He is part of a prominent research team at the Bob Champion Research & Education Building, collaborating with leading scientists like Prof. Colin Cooper and Dr. Daniel Brewer, focusing on metabolic health and urological cancers.